The New Toolbox for Reducing Painful Sex in Menopause

A Stanford review surveys GSM treatments — hormonal, nonhormonal, and device-based — without reporting a single effect size

Journal: Current Opinion in Obstetrics & Gynecology | Published: 2026-02-04 | Type: Review | PMID: 41640134 Authors: Cahill EP (Stanford University School of Medicine, Palo Alto, CA) Funding/COI: Not listed

Summary

Genitourinary syndrome of menopause (GSM) — the constellation of vaginal atrophy, dyspareunia, and urinary symptoms driven by estrogen decline — is the subject of this narrative review from Stanford. Cahill surveys the treatment landscape: local and systemic estrogen, selective estrogen receptor modulators (SERMs), and nonhormonal options including hyaluronic acid and sexual devices. The review also flags emerging literature on GSM in LGBTQ+ populations and non-partnered women, a population largely absent from the underlying trial data.

Claims

• GSM produces genital, sexual, and urinary symptoms that compound one another
• Effective treatment options span behavioral, nonhormonal (hyaluronic acid, devices), and hormonal (local estrogen, SERMs) modalities
• New clinical guidelines on GSM were published in 2025–2026
• Literature increasingly includes menopause experiences outside the heterosexual, partnered, cisgender framework
• Multiple modalities can be used concurrently

Study Quality

This is a narrative review in Current Opinion in Obstetrics & Gynecology — a journal whose explicit editorial model is expert opinion, not systematic synthesis. There is no PRISMA flow diagram, no predefined search strategy, no quality assessment of included studies, and no effect sizes anywhere in the abstract. The author selects which literature to highlight; what gets left out is invisible to the reader.

The abstract is essentially a table of contents for what the full paper discusses. Without the full text, it is impossible to evaluate which specific trials are cited, what their sample sizes and risk-of-bias ratings are, or whether the "emerging" nonhormonal options have RCT-level support or are based on small observational data.

Red Flags

• No quantitative findings reported — not a single odds ratio, mean difference, or response rate in the abstract
• Narrative review design: cherry-picking risk is inherent and cannot be assessed without full text
• No funding source disclosed for a Stanford-affiliated author — notable given industry interest in SERM and device markets
• No COI statement — also notable
• Current Opinion journals are explicitly designed for expert perspective, not evidence synthesis; the bar for publication is lower than for systematic reviews
• Hyaluronic acid and sexual devices are mentioned alongside estrogen with no apparent distinction in evidence quality

Strengths

• Covers the full treatment spectrum in a single document, useful for clinicians needing orientation
• Explicitly addresses LGBTQ+ and non-partnered populations — a real gap in most GSM literature
• Tied to newly released 2026 clinical guidelines, giving it currency
• Single academic author from a research institution (not a pharma-sponsored writing group)

Verdict

This is a map, not a measurement. It tells you what treatments exist and gestures at new guidelines, but offers no data of its own and no rigorous accounting of which options are evidence-backed versus promising-but-unproven. Worth reading as a quick orientation to the GSM treatment landscape and the 2026 guidelines, but any specific claim about efficacy needs to be traced back to the primary sources it cites — which this abstract does not surface.